Alzheimer's Drug Approved by Health Canada
Lecanemab, a lab-made antibody, aims to slow the early stages of Alzheimer's disease by targeting plaques in the brain.
According to the Alzheimer Society of Canada, lecanemab is the first disease-modifying Alzheimer's treatment approved for use in the country.
Lecanemab is not a cure and cannot reverse the disease or restore lost memories.
The conditional approval of lecanemab is being called a positive development, raising questions about its effectiveness and availability in Canada.
- Lecanemab is given by intravenous infusion.
- It targets the buildup of amyloid plaque in the brain, a hallmark of Alzheimer's disease.
Author's summary: Lecanemab approved to slow early Alzheimer's.
Photo: getty images/istockphoto / wildpixel
More News
- Rack Centre Partners with EdgeNext to Launch Content Delivery Network (CDN) and Cloud Hosting Services in Nigeria | Africa24 TV
- McDonalds along busy Cambridge road wants to open for longer
- Indigenous Australian who confronted King Charles III says she won't be 'shut down'
- HyunA assures fans she's doing fine after collapsing mid-show in Macau
- 6 shot, 1 killed in trio of NYC shootings Sunday night
- Surrey M25 accident live updates as multi-vehicle crash causes long delays
- Indigenous Australian who confronted King Charles III says she won't be 'shut down'
- Ducks extend streak to seven with 4-1 win over Jets | News.az
- Typhoon Fung-wong blows away from the Philippines, leaving 4 dead and 1.4 million displaced - The Boston Globe
- HyunA faints on stage mid-performance in Macau due to extreme weight loss, issues health update: ‘I don’t remember anything’